BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28760854)

  • 1. Oncogenic KRAS and p53 Loss Drive Gastric Tumorigenesis in Mice That Can Be Attenuated by E-Cadherin Expression.
    Till JE; Yoon C; Kim BJ; Roby K; Addai P; Jonokuchi E; Tang LH; Yoon SS; Ryeom S
    Cancer Res; 2017 Oct; 77(19):5349-5359. PubMed ID: 28760854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS Activation in Gastric Adenocarcinoma Stimulates Epithelial-to-Mesenchymal Transition to Cancer Stem-Like Cells and Promotes Metastasis.
    Yoon C; Till J; Cho SJ; Chang KK; Lin JX; Huang CM; Ryeom S; Yoon SS
    Mol Cancer Res; 2019 Sep; 17(9):1945-1957. PubMed ID: 31217166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic tumour suppressor activity of E-cadherin and p53 in a conditional mouse model for metastatic diffuse-type gastric cancer.
    Shimada S; Mimata A; Sekine M; Mogushi K; Akiyama Y; Fukamachi H; Jonkers J; Tanaka H; Eishi Y; Yuasa Y
    Gut; 2012 Mar; 61(3):344-53. PubMed ID: 21865403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E-Cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma.
    Sinkevicius KW; Bellaria KJ; Barrios J; Pessina P; Gupta M; Brainson CF; Bronson RT; Kim CF
    Am J Respir Cell Mol Biol; 2018 Aug; 59(2):237-245. PubMed ID: 29447458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperativity of E-cadherin and Smad4 loss to promote diffuse-type gastric adenocarcinoma and metastasis.
    Park JW; Jang SH; Park DM; Lim NJ; Deng C; Kim DY; Green JE; Kim HK
    Mol Cancer Res; 2014 Aug; 12(8):1088-99. PubMed ID: 24784840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.
    Ottenhof NA; de Wilde RF; Morsink FH; de Leng WW; Ausems MG; Morreau H; van Hillegersberg R; Offerhaus GJ; Milne AN
    Hum Pathol; 2012 Mar; 43(3):457-61. PubMed ID: 21992816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations.
    Seidlitz T; Chen YT; Uhlemann H; Schölch S; Kochall S; Merker SR; Klimova A; Hennig A; Schweitzer C; Pape K; Baretton GB; Welsch T; Aust DE; Weitz J; Koo BK; Stange DE
    Gastroenterology; 2019 Dec; 157(6):1599-1614.e2. PubMed ID: 31585123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three types of metaplasia model through Kras activation, Pten deletion, or Cdh1 deletion in the gastric epithelium.
    Kinoshita H; Hayakawa Y; Konishi M; Hata M; Tsuboi M; Hayata Y; Hikiba Y; Ihara S; Nakagawa H; Ikenoue T; Ushiku T; Fukayama M; Hirata Y; Koike K
    J Pathol; 2019 Jan; 247(1):35-47. PubMed ID: 30168144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of Gastric Cancer by Successive Oncogenic Activation in the Corpus.
    Douchi D; Yamamura A; Matsuo J; Melissa Lim YH; Nuttonmanit N; Shimura M; Suda K; Chen S; Pang S; Kohu K; Abe T; Shioi G; Kim G; Shabbir A; Srivastava S; Unno M; Bok-Yan So J; Teh M; Yeoh KG; Chuang LSH; Ito Y
    Gastroenterology; 2021 Dec; 161(6):1907-1923.e26. PubMed ID: 34391772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53.
    Licciulli S; Avila JL; Hanlon L; Troutman S; Cesaroni M; Kota S; Keith B; Simon MC; Puré E; Radtke F; Capobianco AJ; Kissil JL
    Cancer Res; 2013 Oct; 73(19):5974-84. PubMed ID: 23943799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of E-cadherin expression in gastric intestinal metaplasia and later stage p53 altered expression in gastric carcinogenesis.
    Mingchao ; Devereux TR; Stockton P; Sun K; Sills RC; Clayton N; Portier M; Flake G
    Exp Toxicol Pathol; 2001 Sep; 53(4):237-46. PubMed ID: 11665847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of E-cadherin, beta-catenin, CD44s and CD44v6 in gastric adenocarcinoma: relationship with lymph node metastasis.
    Joo M; Lee HK; Kang YK
    Anticancer Res; 2003; 23(2B):1581-8. PubMed ID: 12820426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
    Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
    J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Kasinski AL; Slack FJ
    Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic evaluation of immunohistochemical E-cadherin expression in human gastric carcinomas.
    Shino Y; Watanabe A; Yamada Y; Tanase M; Yamada T; Matsuda M; Yamashita J; Tatsumi M; Miwa T; Nakano H
    Cancer; 1995 Dec; 76(11):2193-201. PubMed ID: 8635021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA ploidy, expression of p53 protein and metastatic behaviour of gastric carcinoma.
    Xin Y; Zhao F; Wu D; Wang Y; Xu L; Curran B; Leader M; Henry K
    Chin Med Sci J; 1996 Sep; 11(3):147-51. PubMed ID: 9387398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between E-cadherin gene mutation and p53 gene mutation, p53 accumulation, Bcl-2 expression and Ki-67 staining in diffuse-type gastric carcinoma.
    Fricke E; Keller G; Becker I; Rosivatz E; Schott C; Plaschke S; Rudelius M; Hermannstädter C; Busch R; Höfler H; Becker KF; Luber B
    Int J Cancer; 2003 Mar; 104(1):60-5. PubMed ID: 12532420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Mutant
    Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
    Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Deneka AY; Kopp MC; Nikonova AS; Gaponova AV; Kiseleva AA; Hensley HH; Flieder DB; Serebriiskii IG; Golemis EA
    Cancer Res; 2021 Jul; 81(13):3717-3726. PubMed ID: 34006524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.